P
Pascal Finetti
Researcher at French Institute of Health and Medical Research
Publications - 162
Citations - 9459
Pascal Finetti is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 49, co-authored 127 publications receiving 8410 citations. Previous affiliations of Pascal Finetti include Aix-Marseille University.
Papers
More filters
Journal ArticleDOI
Gene expression profiling of breast cell lines identifies potential new basal markers
E Charafe-Jauffret,Christophe Ginestier,Florence Monville,Pascal Finetti,José Adélaïde,Nathalie Cervera,S Fekairi,Luc Xerri,Jocelyne Jacquemier,David Jérémie Birnbaum,François Bertucci +10 more
TL;DR: The BCL basal/luminal signature correctly re-classified the published series of tumour samples that originally served to identify the molecular subtypes, suggesting that the identified markers should be useful for tumour classification and might represent promising targets for disease management.
Journal ArticleDOI
How basal are triple-negative breast cancers?
François Bertucci,Pascal Finetti,Nathalie Cervera,Benjamin Esterni,Fabienne Hermitte,Patrice Viens,Daniel Birnbaum +6 more
TL;DR: It is revealed that TN BCs represent a more heterogeneous group than basal BCs, including basal and nonbasal tumors very different both at the histoclinical and molecular level, notably for mRNA expression of molecules targeted by specific therapies under evaluation in clinical trials.
Journal ArticleDOI
Prognostic and predictive value of PDL1 expression in breast cancer
Renaud Sabatier,Pascal Finetti,Emilie Mamessier,José Adélaïde,Max Chaffanet,Ali Hr,Patrice Viens,Patrice Viens,Carlos Caldas,Daniel Birnbaum,François Bertucci,François Bertucci +11 more
TL;DR: PDL1 upregulation, more frequent in basal breast cancers, was associated with increased T-cell cytotoxic immune response and better survival and response to chemotherapy, and reactivation of dormant tumor-infiltrating lymphocytes by PDL1-inhibitors could represent promising strategy.
Journal ArticleDOI
Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters.
François Bertucci,Sébastien Salas,Séverine Eysteries,Valéry Nasser,Pascal Finetti,Christophe Ginestier,Emmanuelle Charafe-Jauffret,Béatrice Loriod,Loïc Bachelart,Jérôme Montfort,Geneviève Victorero,Frédéric Viret,Vincent Ollendorff,Vincent Fert,Marc Giovaninni,Jean-Robert Delpero,Catherine Nguyen,Patrice Viens,Geneviève Monges,Daniel Birnbaum,Rémi Houlgatte +20 more
TL;DR: DNA microarrays may provide means to improve the classification of CRC, provide new potential targets against carcinogenesis and new diagnostic and/or prognostic markers and therapeutic targets, and bring new insights into underlying molecular mechanisms.
Journal ArticleDOI
Integrated profiling of basal and luminal breast cancers.
José Adélaïde,Pascal Finetti,Ismahane Bekhouche,Laetitia Repellini,Jeannine Geneix,Fabrice Sircoulomb,Emmanuelle Charafe-Jauffret,Nathalie Cervera,Jérôme Desplans,Daniel Parzy,Eric F.P.M. Schoenmakers,Patrice Viens,Jocelyne Jacquemier,Daniel Birnbaum,François Bertucci,Max Chaffanet +15 more
TL;DR: It is shown that gain of 10p is a new alteration in basal breast cancer and that a subregion of the 8p12 amplification is specific of luminal tumors, which supports the existence of specific oncogenic pathways in basal and luminal breast cancers.